In CPVT cardiomyocytes with the RyR2 variant R176Q, a viral vector containing a CaMKII inhibitor (autocamtide‐2‐related inhibitory peptide, AAV9‐GFP‐AIP) completely suppressed the abnormal increase in spontaneous Ca2+ transients, suggesting that CaMKII suppression represents a potential therapy for CPVT.127. Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.